Search This Blog

Friday, June 20, 2025

New Data Shows Lexicon's Diabetes Drug Effective Across All Kidney Function Levels - ADA

Lexicon Pharmaceuticals (LXRX) will present clinical data at the 85th ADA Scientific Sessions on June 20-23, 2025, in Chicago. The presentation focuses on sotagliflozin's ability to reduce hypoglycemic events in type 1 diabetes patients across different kidney function levels, categorized by eGFR ranges. Dr. M. Belinda Hardin will deliver an oral presentation on June 22 discussing these findings. Additionally, Lexicon will present topline results from their PROGRESS Phase 2b study of pilavapadin (LX9211), evaluating its effectiveness in treating diabetic peripheral neuropathic pain. The presentations align with ADA's 2025 Standards of Care emphasis on preventing hypoglycemia in type 1 diabetes management.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.